Neurocrine Biosciences Shares Down 8% Following Q4 Ingrezza Revenue Miss
<p><a href='https://financialmodelingprep.com/financial-summary/NBIX'>Neurocrine Biosciences, Inc. (NASDAQ:NBIX) </a>shares dropped more than 8% on Friday following the company’s reported preliminary Q4 Ingrezza net revenues, which came in at $301 million ($296 million + $5 million inventory), missing the $305 million consensus estimate. The results were driven by 56,400 unadjusted scripts representing 8% quarter-over-quarter volume growth.</p>
<p>Net pricing saw a slight decline to around $5,300 per script as rebates and discounts overcame the impact of a 4.5% list price increase in Dec 2021. Analysts at Oppenheimer believe this level of net pricing is relatively sustainable over the long term as the company has a solid track record of rational pricing. Analysts added they are encouraged by Ingrezza's volume driven growth despite continued COVID-19 headwinds and look forward to important catalysts in 2022, including sales guidance on Feb 11. </p

NASDAQ:NBIX